SAVIMS

SAVIMS logo white
Menu

Resource Type

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Summary of Pfizer-BioNTech COVID-19 Vaccine EUA Briefing Document

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: U.S. Food and Drug Administration. (2020). Vaccines and related biological products advisory committee meeting December 10, 2020 FDA briefing document Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/media/144246/download Summary: On December 10, 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed Pfizer-BioNTech’s COVID-19 vaccine, BNT162b2, which received an Emergency Use Authorization (EUA) request on November 20, […]

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Understanding Efficacy and Effectiveness of Vaccines

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Joi, P. (2020). What is the difference between efficacy and effectiveness? Gavi, the Vaccine Alliance. Retrieved from https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness Summary: Efficacy and effectiveness are two crucial terms in vaccine science, often conflated but distinct. Efficacy refers to the performance of a vaccine under ideal, controlled conditions, typically demonstrated in clinical trials where a vaccinated group

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Monitoring COVID-19 Vaccine Safety: FDA’s Comprehensive Plan

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Anderson, S. (2020). CBER plans for monitoring COVID-19 vaccine safety and effectiveness. Vaccines and Related Biological Products Advisory Committee Meeting, FDA. Summary: The FDA’s Centre for Biologics Evaluation and Research (CBER) presented its comprehensive strategy for monitoring the safety and effectiveness of COVID-19 vaccines during the VRBPAC meeting on October 22, 2020. The approach

Cancer, Peer-reviewed evidence, Reference Library, Resource Type, Treatment

Ivermectin as an Anticancer Drug: Mechanisms and Potential

| | Cancer, Peer-reviewed evidence, Reference Library, Resource Type, Treatment

Reference: Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. https://doi.org/10.1016/j.phrs.2020.105207 Summary: Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to research on the virus,

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Phase 3 Clinical Trial of COVID-19 Vaccine Initiated

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: National Institutes of Health. (2020, July 27). Phase 3 clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins Summary: The National Institutes of Health (NIH) has commenced a Phase 3 clinical trial to assess the efficacy of the investigational mRNA-1273 vaccine, co-developed by Moderna, Inc. and NIH’s National Institute of Allergy and Infectious Diseases

COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

The Retraction of a Controversial Study on COVID-19 Treatments

| | COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, published online May 22, https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: In June 2020, The Lancet announced the retraction of a significant study assessing the effectiveness of hydroxychloroquine

COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Hydroxychloroquine and Chloroquine in COVID-19 Treatment: A Multinational Analysis

| | COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, 395(10240), 1820-1830. https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: The study evaluates the efficacy of hydroxychloroquine and chloroquine, either alone or in combination with macrolides, in treating COVID-19

COVID-19, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

An Effective At-Home Treatment for Viral Infections

| | COVID-19, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: Levy, T. E. (2020). An at-home treatment that can cure any virus, including coronavirus. Retrieved from www.PeakEnergy.com Summary: The article discusses a simple and inexpensive treatment for viral infections, including COVID-19, using 3% hydrogen peroxide. Originally conceptualised by Dr. Charles Farr, this therapy targets infected cells rather than the viruses themselves, which cannot be

Ethics, Other scientific evidence, Reference Library, Resource Type, Treatment

South African Good Clinical Practice Guidelines: Overview

| | Ethics, Other scientific evidence, Reference Library, Resource Type, Treatment

Reference: Department of Health. (2020). South African Good Clinical Practice: Clinical Trial Guidelines (3rd ed.). Pretoria, South Africa. Summary: The South African Good Clinical Practice (SA GCP) Guidelines, first established in 2006 and revised in 2020, provide a framework for conducting ethical and scientifically sound clinical trials within South Africa. Mandated by national health legislation,

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162 RNA-Based COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Pfizer. (2020). PF-07302048 (BNT162 RNA-Based COVID-19 vaccines) protocol C4591001. Summary: The document outlines the Phase 1/2/3 clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of BNT162 RNA-based COVID-19 vaccines, developed by Pfizer and BioNTech. The trial investigates two vaccine candidates: BNT162b1, encoding the receptor-binding domain (RBD), and BNT162b2, encoding the prefusion spike

Scroll to Top